Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (2010 - 2026)

Pacific Biosciences Of California's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 98.06% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$128.6 million (up 80.45% YoY), while the FY2025 annual figure was -$546.4 million, down 76.34% from the prior year.
• Net Income towards Common Stockholders was -$8.3 million for Q1 2026 at Pacific Biosciences Of California, up from -$40.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.4 million in Q4 2024 to a low of -$426.1 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$87.4 million across 5 years, with a median of -$71.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 102.89% in 2024, then tumbled 1802.7% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$84.4 million in 2022, then advanced by 2.8% to -$82.0 million in 2023, then surged by 102.89% to $2.4 million in 2024, then sank by 1802.7% to -$40.4 million in 2025, then surged by 79.5% to -$8.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$8.3 million (Q1 2026), -$40.4 million (Q4 2025), and -$38.0 million (Q3 2025), per Business Quant data.